PD-L1 t-haNK

Phase 2Biologic

IImmunityBio, Inc.

PD-L1 t-haNK is one of 130 biologic programs targeting Metastatic Solid Cancers. It is currently in Phase 2.

Indications

Total Trials

Active Trials

129

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Solid CancersActive, not recruiting

Pancreatic CancerActive, not recruiting

GlioblastomaActive, not recruiting

Head and Neck CancerActive, not recruiting

Metastatic Solid CancersPhase 1

Active, not recruiting

Pancreatic CancerPhase 2

Active, not recruiting

GlioblastomaPhase 2

Active, not recruiting

Head and Neck CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

335 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

PD-L1 t-haNK

IImmunityBio, Inc.

Phase 2

1 2

Medrol

Pfizer

Preclinical

1 3

Byetta

AstraZeneca

Preclinical

1 4

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 6

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 7

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 8

Active Comparator

Moderna

Preclinical

1 9

Sulfonylureas

Eli Lilly

Preclinical

1 10

HS-20093

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Head and Neck Cancer

NCT06239220

Q4 2027

Phase 2Active, not recruiting

Head and Neck Cancer

NCT04847466

Q4 2030

Phase 2Active, not recruiting

Glioblastoma

NCT06061809

Clinical

Trials by Indication[1]

Head and Neck Cancer2 trials

Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04847466·18 enrolled

A Phase 2 Trial of PD-L1 t-haNK, NAI IL-15 Superagonist (Anktiva), and Cetuximab for Immunotherapy-treated Patients With Recurrent, Metastatic HNSCC (QUILT-505)

Recruiting·GGlenn J. Hanna·Phase 2·NCT06239220·25 enrolled

Pancreatic Cancer1 trial

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Active, not recruiting·IImmunityBio, Inc.·Phase 2·NCT04390399·328 enrolled

Triple-Negative Breast Cancer1 trial

A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies

Terminated·IImmunityBio, Inc.·Phase 1/2·NCT04927884·3 enrolled

Metastatic Solid Cancers1 trial

QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers

Active, not recruiting·IImmunityBio, Inc.·Phase 1·NCT04050709·16 enrolled

Glioblastoma1 trial

Open-Label, Single-Arm Phase 2 Study of Nogapendekin Alfa Inbakicept, PD-L1 t-haNK, Bevacizumab and Randomized Phase 2B Study of Nogapendekin Alfa Inbakicept, Bevacizumab, and Tumor Treatment Fields With or Without PD-L1 t-haNK in Participants With Recurrent or Progressive Glioblastoma

Active, not recruiting·IImmunityBio, Inc.·Phase 2·NCT06061809·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for PD-L1 t-haNK. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PD-L1 t-haNK compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PD-L1 t-haNK. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ImmunityBio, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: IImmunityBio, Inc.

PD-L1 t-haNK

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Q4 2030

Trials by Indication[1]

Head and Neck Cancer2 trials

Pancreatic Cancer1 trial

Triple-Negative Breast Cancer1 trial

Metastatic Solid Cancers1 trial

Glioblastoma1 trial

References

Drug Info

Quick Facts

Related News